Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin
- PMID: 1649577
- PMCID: PMC245145
- DOI: 10.1128/AAC.35.5.998
Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin
Abstract
Mersacidin, a new peptide antibiotic, was four- to eightfold less active (MIC for 90% of isolates, 8 micrograms/ml) than vancomycin, teicoplanin, or daptomycin against Staphylococcus aureus. Coagulase-negative staphylococci were inhibited by 8 micrograms/ml, and the MICs of mersacidin for hemolytic streptococci and Streptococcus pneumoniae were 4 to 8 micrograms/ml. The mersacidin MICs for anaerobic organisms were as follows: Clostridium perfringens, 4 micrograms/ml; Propionibacterium acnes, 8 micrograms/ml; peptococci, 1 microgram/ml; and peptostreptococci, 8 micrograms/ml. Mersacidin had no activity against members of the family Enterobacteriaceae, Neisseria and Haemophilus species, or Pseudomonas aeruginosa. The size of the inoculum, the pH of the assay (5.5 to 7.5), the type of medium, and the anaerobic conditions had minimal effects on the MICs and MBCs of mersacidin. Overall, mersacidin proved less active than available glycopeptides and peptolides.
Similar articles
-
In vitro activity of the new glycopeptide decaplanin.Eur J Clin Microbiol Infect Dis. 1992 May;11(5):458-62. doi: 10.1007/BF01961864. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1330562
-
In vitro activity of LY264826 compared to other glycopeptides and daptomycin.Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181-4. doi: 10.1016/0732-8893(91)90056-l. Diagn Microbiol Infect Dis. 1991. PMID: 1651826
-
In vitro activity of LY146032 (daptomycin), a new peptolide.Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208. Eur J Clin Microbiol. 1987. PMID: 3032611
-
Microbiological properties of teicoplanin.J Antimicrob Chemother. 1988 Jan;21 Suppl A:1-13. doi: 10.1093/jac/21.suppl_a.1. J Antimicrob Chemother. 1988. PMID: 2965119 Review.
-
Resistance to vancomycin and teicoplanin: an emerging clinical problem.Clin Microbiol Rev. 1990 Jul;3(3):280-91. doi: 10.1128/CMR.3.3.280. Clin Microbiol Rev. 1990. PMID: 2143434 Free PMC article. Review.
Cited by
-
Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment for Staphylococcus aureus Infections in Animals and Humans.Antibiotics (Basel). 2023 Jul 30;12(8):1256. doi: 10.3390/antibiotics12081256. Antibiotics (Basel). 2023. PMID: 37627676 Free PMC article. Review.
-
Aminovinyl Cysteine Containing Peptides: A Unique Motif That Imparts Key Biological Activity.JACS Au. 2021 Sep 15;1(10):1527-1540. doi: 10.1021/jacsau.1c00308. eCollection 2021 Oct 25. JACS Au. 2021. PMID: 34723257 Free PMC article. Review.
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 2000 Sep;39(3):167-83. doi: 10.2165/00003088-200039030-00001. Clin Pharmacokinet. 2000. PMID: 11020133 Review.
-
Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.Probiotics Antimicrob Proteins. 2012 Dec;4(4):259-72. doi: 10.1007/s12602-012-9116-9. Probiotics Antimicrob Proteins. 2012. PMID: 26782186
-
Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.Antimicrob Agents Chemother. 2000 Dec;44(12):3447-50. doi: 10.1128/AAC.44.12.3447-3450.2000. Antimicrob Agents Chemother. 2000. PMID: 11083657 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical